What does this research mean for the field?

An 8 mg/kg dose of anti-thymocyte globulin (ATG) is as effective as a 10 mg/kg dose for overall survival in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia, with superior outcomes in patients receiving co-transplantation of cord blood and bone marrow. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To compare the 3-year overall survival of 8 mg/kg and 10 mg/kg anti-thymocyte globulin in patients undergoing allogeneic stem cell transplantation for transfusion-dependent thalassemia.

February 16, 2026Open Access

Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical trial

Key Points

To compare the 3-year overall survival of 8 mg/kg and 10 mg/kg anti-thymocyte globulin in patients undergoing allogeneic stem cell transplantation for transfusion-dependent thalassemia.
Randomized clinical trial design
Between 2015 and 2023, 295 patients were randomized to 8 mg/kg or 10 mg/kg ATG
Primary endpoints included 3-year overall survival and thalassemia-free survival
Survival analysis conducted using Kaplan–Meier method
Both ATG dosage groups had similar 3-year overall survival rates (98.6% vs 95.3%)
No significant differences in graft-versus-host disease or graft failure between the groups
In the subgroup with cord blood and bone marrow co-transplantation, the 8 mg/kg group showed higher overall survival (100% vs 86.5%, p = 0.012)

Abstract

Background: Anti-thymocyte globulin (ATG) is used as prophylaxis for graft-versus-host disease (GvHD) and graft failure (GF) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with transfusion-dependent thalassemia (TDT). However, the optimal dose of ATG remains unknown. Objectives: To compare the 3-year overall survival (OS) of 8 mg/kg and 10 mg/kg ATG in allo-HSCT for patients with TDT. Methods: We compared two different doses of ATG for patients with TDT undergoing allo-HSCT from HLA-matched sibling donors (MSDs). Between 2015 and 2023, 147 patients were randomized to the 8 mg/kg ATG group and 148 patients to the 10 mg/kg ATG group. Primary endpoints were 3-year OS and thalassemia-free survival (TFS). Survival analysis for OS and TFS was performed using the Kaplan–Meier method. Results: The 8 and 10 mg/kg ATG groups had similar 3-year OS and TFS (both 98.6% (95% confidence interval CI: 96.8–100) vs 95.3% (95% CI: 91.9–98.7), p = 0.066). There were no significant differences in graft-versus-host disease and GF between groups. In the subgroup with co-transplantation of cord blood (CB) and bone marrow (BM) as stem cell sources, the 8 mg/kg ATG group had higher 3-year OS and TFS than the 10 mg/kg ATG group (both 100% (95% CI: not applicable) vs 86.5% (95% CI: 75.5–98.2), p = 0.012). Conclusion: This study provides evidence that an 8 mg/kg ATG is an effective treatment for TDT transplanted from MSDs. A notable finding was the superior survival associated with the 8 mg/kg ATG in the CB and BM co-transplantation. These results provide critical evidence for guiding ATG dosing strategies in allo-HSCT for TDT, particularly in the context of stem cell source selection. Design: Open-label, randomized clinical trial. Trial registration: ChiCTR-IPR-15005779 (Chinese Clinical Trial Registry; https://www.chictr.org.cn/showproj.html?proj=10208 ; date of registration: December 29, 2014).

Read Full Paperexternally

Mark Helpful

Bookmark

Relay

View Full Paper